Results 41 to 50 of about 47,734 (283)

Itraconazole or Amphotericin B for Talaromycosis [PDF]

New England Journal of Medicine, 2017
Item does not contain ...
Bruggemann, R.J.M., Bruggemann, R.J.M., van de Veerdonk, F.L., Verweij, P.E.   +3 more
openaire   +6 more sources

Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial

Dermatology Practical & Conceptual, 2016
Background: Few studies have examined the effect of seborrheic dermatitis (SD) and/or its consequent therapy on a patient’s quality of life. Itraconazole has been suggested as an effective therapy for severe SD but its impact on Quality of Life (QoL) in ...
Zaheer Abbas, Seyede Zahra Ghodsi, Robabeh Abedeni   +2 more
doaj   +1 more source

Effects of Cytochrome P450 Inhibitors on Itraconazole and Fluconazole Induced Cytotoxicity in Hepatocytes

Journal of Toxicology, 2009
Itraconazole and fluconazole have been reported to induce hepatotoxicity in patients. The present study was designed to investigate the role of cytochrome P450 inhibitors, SKF 525A, and curcumin pretreatment on the cytotoxicity of antifungal drugs ...
Nhareet Somchit, Chong Sock Ngee, Azhar Yaakob, Zuraini Ahmad, Zainul Amiruddin Zakaria   +4 more
doaj   +1 more source

Efficacy and safety of adding low-dose isotretinoin to itraconazole in the treatment of chronic recurrent dermatophytosis among sample of Iraqi patients: An open-labelled therapeutic clinical comparative study

Indian Journal of Dermatology, 2022
Background: An increasing number of dermatophytosis is seen now in daily clinical practice, with unusual presentations, running a chronic recurrent course and seems to be more resistant to systemic and topical conventional treatments, which necessitate ...
Dooha K Alhamdi, Khalil I Alhamdi
doaj   +1 more source

Itraconazole targets cell cycle heterogeneity in colorectal cancer

Journal of Experimental Medicine, 2018
Cellular dormancy and heterogeneity in cell cycle length provide important explanations for treatment failure after adjuvant therapy with S-phase cytotoxics in colorectal cancer (CRC), yet the molecular control of the dormant versus cycling state remains
S. Buczacki, S. Popova, E. Biggs, Chrysa Koukorava, Jon N. Buzzelli, L. Vermeulen, L. Hazelwood, Hayley E. Francies, M. Garnett, D. Winton   +9 more
semanticscholar   +1 more source

Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole

Frontiers in Oncology, 2020
Oral Squamous Cell Carcinoma (OSCC) presents an important challenge for the health systems worldwide. Thus, unraveling the biological mechanisms involved in OSCC pathogenesis is essential to the discovery of new drugs with anticancer potential.
Raíza Dias Freitas, Raíza Dias Freitas, Rosane Borges Dias, Rosane Borges Dias, Manuela Torres Andion Vidal, Manuela Torres Andion Vidal, Ludmila de Faro Valverde, Ludmila de Faro Valverde, Rafaela Gomes Alves Costa, Andresa Karen Andrade Damasceno, Caroline Brandi Schlaepfer Sales, Leonardo de Oliveira Siquara da Rocha, Mitermayer Galvão dos Reis, Mitermayer Galvão dos Reis, Milena Botelho Pereira Soares, Ricardo Della Coletta, Thiago Almeida Pereira, Daniel Pereira Bezerra, Clarissa Araújo Gurgel Rocha, Clarissa Araújo Gurgel Rocha, Clarissa Araújo Gurgel Rocha   +20 more
doaj   +1 more source

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects

Cancer Chemotherapy and Pharmacology, 2019
Purpose Zanubrutinib (BGB-3111) is a potent Bruton’s tyrosine kinase inhibitor with promising clinical activity in B-cell malignancies. Zanubrutinib was shown to be mainly metabolized through cytochrome P450 3A (CYP3A) in vitro.
S. Mu, Zhiyu Tang, W. Novotny, M. Tawashi, Ta‐Kai Li, Y. Ou, S. Sahasranaman   +6 more
semanticscholar   +1 more source

Antifungal Susceptibility Pattern of Non - Dermatophytic Fungi Causing Onychomycosis

Nepal Journal of Dermatology, Venereology & Leprology, 2020
Introduction: Non-dermatophytic molds (NDM) are filamentous fungi or yeast, commonly found in nature as saprophytes and plant pathogens. The incidence of onychomycosis due to NDM is 1.45 – 16.6%.
Apurva Kaushal, Pratik Gahalaut, R K Goyal, Neni Agarwal, Nitin Mishra, Madhur Kant Rastogi   +5 more
doaj   +3 more sources

Itraconazole in dermatology

Journal of Dermatological Treatment, 1992
Itraconazole is a triazole analogue with a broad spectrum of antifungal activity, which covers yeasts and moulds. It is active against dermatophytes, candidal and pityrosporum yeasts, as well as a number of fungi which cause subcutaneous and systemic infection. It is well absorbed and has significantly fewer side-effects than systemic imidazoles. It is
openaire   +3 more sources

Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database

British Journal of Clinical Pharmacology, EarlyView.
Aims Spontaneous reporting of adverse drug reactions (ADR) after a product has reached the market is essential for drug safety. This study analysed patient ADR reports and compared them with reports from the Japanese Adverse Drug Event Report (JADER) database to identify differences and trends.
Masami Tsuchiya, Ryohkan Funakoshi, Koichi Masuyama, Nariyasu Mano, Satoko Hori, Taku Obara   +5 more
wiley   +1 more source